Tycoon Group Holdings Limited (HK:3390)
:3390
Want to see HK:3390 full AI Analyst Report?
Top Page
Tycoon Group Holdings Limited
(3390)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$0.28
▼(-5.17% Downside)
Action:ReiteratedDate:04/19/26
The score is driven primarily by improving fundamentals (2025 revenue rebound and return to positive operating/free cash flow) but capped by very thin margins and high year-to-year volatility in profitability and cash flows. Technicals add pressure due to a weak trend setup (below key moving averages and negative MACD), while valuation is only moderately supportive with a mid-range P/E and no dividend yield data.
Positive Factors
Revenue and cash flow recovery
A clear rebound in 2025 revenue and the return to positive operating and free cash flow materially improves the company's ability to self-fund operations, service obligations and invest in distribution or inventory. This restores financial flexibility and reduces near-term reliance on external financing for working capital or growth initiatives.
Negative Factors
Thin and eroding margins
Very thin operating and net margins limit the firm's ability to absorb cost inflation, invest in growth, or withstand price competition. The decline in gross margin points to upstream cost pressure or weaker pricing power; structurally low margins constrain long-term profitability and reduce returns even if revenue recovers.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and cash flow recovery
A clear rebound in 2025 revenue and the return to positive operating and free cash flow materially improves the company's ability to self-fund operations, service obligations and invest in distribution or inventory. This restores financial flexibility and reduces near-term reliance on external financing for working capital or growth initiatives.
Read all positive factors
Tycoon Group Holdings Limited (3390) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$236.91M
Dividend Yield28%
Average Volume (3M)1.30M
Price to Earnings (P/E)15.2
Beta (1Y)0.05
Revenue Growth25.18%
EPS Growth245.83%
CountryHK
Employees258
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.03
Shares Outstanding894,000,000
10 Day Avg. Volume1,126,200
30 Day Avg. Volume1,299,466
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.44
Price to Sales (P/S)0.22
P/FCF Ratio2.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tycoon Group Holdings Limited Business Overview & Revenue Model
Company Description
Tycoon Group Holdings Limited, an investment holding company, distributes and retails a suite of health and well-being related products in Hong Kong, Mainland China, Macau, and internationally. It operates through three segments: Distribution, E-C...
How the Company Makes Money
The company primarily makes money by purchasing healthcare products (notably pharmaceuticals and related medical/health products) from manufacturers and suppliers and selling them through its distribution network to downstream customers, earning r...
Tycoon Group Holdings Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
62
Positive
Cash Flow
54
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.10B | 876.04M | 1.20B | 1.19B | 888.87M |
| Gross Profit | 245.47M | 232.66M | 321.10M | 243.53M | 135.01M |
| EBITDA | 64.59M | 35.85M | 356.41M | 82.89M | 8.91M |
| Net Income | 15.67M | 3.24M | 297.32M | 43.75M | -18.82M |
Balance Sheet | |||||
| Total Assets | 1.17B | 1.01B | 988.95M | 1.01B | 881.46M |
| Cash, Cash Equivalents and Short-Term Investments | 70.34M | 34.02M | 39.10M | 74.60M | 71.63M |
| Total Debt | 428.05M | 330.98M | 206.16M | 341.60M | 239.08M |
| Total Liabilities | 625.03M | 516.61M | 445.40M | 718.96M | 620.20M |
| Stockholders Equity | 537.00M | 478.85M | 536.23M | 293.64M | 257.92M |
Cash Flow | |||||
| Free Cash Flow | 96.47M | -78.94M | 7.97M | -64.48M | -50.11M |
| Operating Cash Flow | 96.95M | -76.62M | 11.86M | -63.03M | -42.20M |
| Investing Cash Flow | -25.10M | 48.55M | 45.70M | -9.57M | -26.25M |
| Financing Cash Flow | -35.36M | 25.62M | -92.36M | 68.25M | 14.33M |
Tycoon Group Holdings Limited Technical Analysis
Negative
0.29
Price Trends
0.29
Negative
0.29
Negative
0.31
Negative
Market Momentum
>-0.01
Negative
46.01
Neutral
48.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3390, the sentiment is Negative. The current price of 0.29 is above the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.29, and below the 200-day MA of 0.31, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.01 is Neutral, neither overbought nor oversold. The STOCH value of 48.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3390.
Tycoon Group Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$567.08M | 5.13 | 16.21% | 4.94% | 16.46% | 50.51% | |
59 Neutral | HK$1.76B | -4.72 | -2.70% | ― | -32.11% | -229.14% | |
55 Neutral | HK$303.25M | 24.91 | 1.78% | 5.87% | -13.43% | -72.61% | |
54 Neutral | HK$236.91M | 15.20 | 2.98% | 28.00% | 25.18% | 245.83% | |
54 Neutral | HK$287.98M | -2.55 | -25.22% | 3.16% | -29.10% | -344.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$218.99M | -0.67 | -34.76% | ― | -38.20% | -108.24% |
* Healthcare Sector Average
HK:3390
Tycoon Group Holdings Limited
0.27
-0.15
-36.90%
HK:1110
Kingworld Medicines Group Ltd.
0.49
-0.05
-8.49%
HK:1518
New Century Healthcare Holding Co. Ltd.
0.59
-0.51
-46.36%
HK:1612
Vincent Medical Holdings Limited
0.86
0.50
138.89%
HK:1643
Modern Chinese Medicine Group Co. Ltd.
2.76
2.40
666.67%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.09
0.01
16.25%
Tycoon Group Holdings Limited Corporate Events
Tycoon Group Sets 2026 AGM to Renew Board, Auditor and Share Buyback Mandate
Apr 16, 2026
Tycoon Group Holdings Limited has convened its annual general meeting for 29 May 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025 and hear reports from th...
Tycoon Group Moves to Update Articles for Uncertificated Securities Regime
Apr 16, 2026
Tycoon Group Holdings plans to replace its existing third amended and restated articles of association with a new, fourth amended and restated version to align its corporate constitution with updated Hong Kong listing regulations. The changes are ...
Tycoon Group Profit Surges on 25% Revenue Growth in 2025
Mar 31, 2026
Tycoon Group Holdings Limited reported a strong set of results for the year ended 31 December 2025, with revenue rising 25.2% year on year to HK$1,096.6 million as the group expanded sales of its healthcare and consumer products. Net profit more t...
Tycoon Group Sets Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 12, 2026
Tycoon Group Holdings Limited has scheduled a board meeting for 31 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. The board will also decide whether to recommend a final dividend, a move that cou...
Tycoon Group Forecasts Profit Surge on Revenue Growth and Cost Controls
Mar 5, 2026
Tycoon Group Holdings Limited has issued a positive profit alert, stating that its profit before tax for the year ended 31 December 2025 is expected to rise by at least 200% from about HK$5.5 million in 2024, driven by a revenue increase of no les...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.